UK's NuCana Q4 net loss widens

NuCana

19/03/2026 20:25

Overview

UK biopharma firm's Q4 net loss widened yr/yr

NuCana expects key clinical milestones for lead cancer drug NUC-7738 in 2026

Outlook

NuCana anticipates cash resources will fund operations into 2029

Result Drivers

NON-CASH FINANCE EXPENSE - Co said net loss for the year included £12.6 mln non-cash loss from fair value revaluation of warrants issued in May 2025 financing

HIGHER SHARE-BASED PAYMENTS - Co reported £10 mln in share-based payment expenses for the yr, up from £1.6 mln in 2024

INCREASED PROFESSIONAL FEES - Co incurred £1.4 mln in professional fees related to the issue of warrants in 2025

Company press release: ID:nGNX6gXFY6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
GBP 0
Q4 Net Income
-GBP 2.49 mln
Q4 Operating Income
-GBP 2.80 mln
Q4 Pretax Profit
-GBP 2.63 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)